IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition.
|
release announcing its financial results for the quarter ended
March 31, 2017. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
99.1 hereto, shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such
filing.
|
Item 8.01.
|
Other Events.
|
reporting new clinical and biomarker data from the Companys
CMB305 and G100 monotherapy studies, which data will be presented
at the 2017 Annual Meeting of the American Society of Clinical
Oncology (ASCO) in June.
Current Report on Form 8-K and is incorporated herein by
reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated May 17, 2017.
|
|
|
99.2
|
Press Release, dated May 17, 2017.
|
|
About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA). IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Recent Trading Information
IMMUNE DESIGN CORP. (NASDAQ:IMDZ) closed its last trading session down -0.20 at 6.05 with 91,082 shares trading hands.
